New Triple-Drug cocktail targets untreated follicular lymphoma

NCT ID NCT07585747

First seen May 15, 2026 · Last updated May 15, 2026

Summary

This study tests a combination of three drugs (orelabrutinib, tafasitamab, and lenalidomide) as a first treatment for people with follicular lymphoma, a slow-growing blood cancer. About 27 newly diagnosed adults will receive the drugs to see how well they shrink tumors and control the disease. The goal is to improve response rates while monitoring safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450000, China

  • Institute of Hematology & Blood Diseases Hospital, China

    Tianjin, Tianjin Municipality, 300020, China

  • Qilu Hospital of Shandong Province

    Jinan, Shandong, China

    Contact Phone: •••-•••-••••

  • Shenzhen Second People's Hospital

    Shenzhen, Guangdong, China

    Contact Phone: •••-•••-••••

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, 330000, China

Conditions

Explore the condition pages connected to this study.